These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 15359643)

  • 1. Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy.
    Curti A; Isidori A; Ferri E; Terragna C; Neyroz P; Cellini C; Ratta M; Baccarani M; Lemoli RM
    Leuk Lymphoma; 2004 Jul; 45(7):1419-28. PubMed ID: 15359643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination.
    Motta MR; Castellani S; Rizzi S; Curti A; Gubinelli F; Fogli M; Ferri E; Cellini C; Baccarani M; Lemoli RM
    Br J Haematol; 2003 Apr; 121(2):240-50. PubMed ID: 12694245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
    Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
    J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient presentation of tumor idiotype to autologous T cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients.
    Ratta M; Curti A; Fogli M; Pantucci M; Viscomi G; Tazzari P; Fagnoni F; Vescovini R; Sansoni P; Tura S; Lemoli RM
    Exp Hematol; 2000 Aug; 28(8):931-40. PubMed ID: 10989194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
    Reichardt VL; Milazzo C; Brugger W; Einsele H; Kanz L; Brossart P
    Haematologica; 2003 Oct; 88(10):1139-49. PubMed ID: 14555310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
    Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
    Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells generated from CD34+ progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-alpha are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells.
    Ferlazzo G; Klein J; Paliard X; Wei WZ; Galy A
    J Immunother; 2000 Jan; 23(1):48-58. PubMed ID: 10687137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical-scale generation of dendritic cells in a closed system.
    Sorg RV; Ozcan Z; Brefort T; Fischer J; Ackermann R; Müller M; Wernet P
    J Immunother; 2003; 26(4):374-83. PubMed ID: 12843800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy.
    Wong EC; Maher VE; Hines K; Lee J; Carter CS; Goletz T; Kopp W; Mackall CL; Berzofsky J; Read EJ
    Cytotherapy; 2001; 3(1):19-29. PubMed ID: 12028840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical grade of generation of dendritic cells for immunotherapy.
    Tang D; Tao S; Cao Y; Zhou J; Ma D; Huang W
    J Huazhong Univ Sci Technolog Med Sci; 2007 Jun; 27(3):265-8. PubMed ID: 17641838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination.
    Brabants E; Heyns K; De Smet S; Devreker P; Ingels J; De Cabooter N; Debacker V; Dullaers M; VAN Meerbeeck JP; Vandekerckhove B; Vermaelen KY
    Cytotherapy; 2018 Sep; 20(9):1164-1181. PubMed ID: 30122654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
    Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
    Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of CMRF-44+ monocyte-derived dendritic cells: insights into phenotype and function.
    Vuckovic S; Fearnley DB; Mannering SI; Dekker J; Whyte LF; Hart DN
    Exp Hematol; 1998 Dec; 26(13):1255-64. PubMed ID: 9845382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
    Akiyama Y; Oshita C; Kume A; Iizuka A; Miyata H; Komiyama M; Ashizawa T; Yagoto M; Abe Y; Mitsuya K; Watanabe R; Sugino T; Yamaguchi K; Nakasu Y
    BMC Cancer; 2012 Dec; 12():623. PubMed ID: 23270484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
    Liso A; Stockerl-Goldstein KE; Auffermann-Gretzinger S; Benike CJ; Reichardt V; van Beckhoven A; Rajapaksa R; Engleman EG; Blume KG; Levy R
    Biol Blood Marrow Transplant; 2000; 6(6):621-7. PubMed ID: 11128812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells.
    Eyrich M; Schreiber SC; Rachor J; Krauss J; Pauwels F; Hain J; Wölfl M; Lutz MB; de Vleeschouwer S; Schlegel PG; Van Gool SW
    Cytotherapy; 2014 Jul; 16(7):946-64. PubMed ID: 24831836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of canine monocyte-derived dendritic cells with phenotypic and functional differentiation.
    Wang YS; Chi KH; Liao KW; Liu CC; Cheng CL; Lin YC; Cheng CH; Chu RM
    Can J Vet Res; 2007 Jul; 71(3):165-74. PubMed ID: 17695590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors.
    Dauer M; Obermaier B; Herten J; Haerle C; Pohl K; Rothenfusser S; Schnurr M; Endres S; Eigler A
    J Immunol; 2003 Apr; 170(8):4069-76. PubMed ID: 12682236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
    Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
    Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.
    Babatz J; Röllig C; Löbel B; Folprecht G; Haack M; Günther H; Köhne CH; Ehninger G; Schmitz M; Bornhäuser M
    Cancer Immunol Immunother; 2006 Mar; 55(3):268-76. PubMed ID: 16034561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.